AAKASH GOYAL

Allopathic & Osteopathic Physicians|Family Medicine ALPHARETTA, GA NPI 1700373503

General Payments — all program years on this page

$572.59

  • Category: General Payments
  • Program years: PY2024
  • Record count: 22
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $572.59 across 22 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $540.3221
Education $32.271

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2024 $572.5922

Records — PY2024 (22)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1081876430 Saluda Medical Americas, Inc. $26.50 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1082665109 Neos Therapeutics, LP $19.19 04/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1082671733 Neos Therapeutics, LP $20.89 07/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086195186 Bayer Healthcare Pharmaceuticals Inc. $18.54 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089427671 Daiichi Sankyo Inc. $17.45 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089508512 Currax Pharmaceuticals LLC $13.86 02/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097006513 Novo Nordisk Inc $20.21 02/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097387960 Novo Nordisk Inc $32.27 02/08/2024 Education Undisputed 01/23/2026 View at CMS
1097469745 Novo Nordisk Inc $24.48 07/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103826108 ABBVIE INC. $23.50 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104395175 AstraZeneca Pharmaceuticals LP $18.83 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104503338 AstraZeneca Pharmaceuticals LP $19.75 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114680736 Exact Sciences Corporation $20.44 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114680743 Exact Sciences Corporation $14.79 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131824386 PFIZER INC. $16.14 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131872491 PFIZER INC. $21.55 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136000935 Lilly USA, LLC $16.26 05/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136000937 Lilly USA, LLC $18.50 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136001867 Lilly USA, LLC $14.96 06/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142205677 ABIOMED $26.98 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142205679 ABIOMED $146.96 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146766754 IDORSIA PHARMACEUTICALS US INC $20.54 02/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.